FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CORT, CRBP and BSX

CEDARHURST, NY / ACCESSWIRE / May 6, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Corcept Therapeutics Incorporated (CORT)

Investors Affected : August 2, 2017 - February 5, 2019

A class action has commenced on behalf of certain shareholders in Corcept Therapeutics Incorporated. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company had improperly paid doctors to promote its drug Korlym; (2) the Company aggressively promoted Korlym for off-label uses; (3) the Company's sole specialty pharmacy was a related party; (4) the Company artificially inflated its revenue and sales using illicit sales practices through a related party; (5) such practices are reasonably likely to lead to regulatory scrutiny; and (6) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/corcept-therapeutics-incorporated-loss-submission-form/?id=1412&from=1

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Investors Affected : November 14, 2016 - February 28, 2019

A class action has commenced on behalf of certain shareholders in Corbus Pharmaceuticals Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Corbus improperly changed the primary efficacy endpoint for the clinical study of its drug candidate, Lenabasum, after the results were unblinded to Corbus; (2) Corbus reported a one-sided p value, not the traditional two-sided p value normally reported in clinical trials, in an effort to conceal the fact that the study results did not have statistical significance; and (3) as a result, Corbus' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Shareholders may find more information at https://kclasslaw.com/securities/corbus-pharmaceutical-holdings-inc-loss-submission-form/?id=1412&from=1

Boston Scientific Corporation (BSX)

Investors Affected : February 26, 2015 - April 16, 2019

A class action has commenced on behalf of certain shareholders in Boston Scientific Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Boston Scientific's surgical mesh products indicated for the transvaginal repair of pelvic organ prolapse ("POP") were unsafe; (ii) accordingly, Boston Scientific's continued marketing and sales of these devices in the United States was unlikely to be sustainable; (iii) separately, the Company had sold vaginal mesh implants containing counterfeit or adulterated resin products imported from China; (iv) the foregoing conduct subjected the Company to a heightened risk of regulatory scrutiny and/or government investigations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/boston-scientific-corporation-loss-submission-form/?id=1412&from=1